A panelist discusses the diverse clinical presentation and complex pathophysiology of seborrheic dermatitis, emphasizing the need for individualized, location-specific treatment strategies and highlighting how emerging therapies may help address overlapping features with other chronic inflammatory skin conditions.
A panelist highlights the evolution of seborrheic dermatitis treatment from traditional antifungals and corticosteroids to newer nonsteroidal options such as phosphodiesterase-4 (PDE4) inhibitors, emphasizing the importance of aligning therapy with patient preferences, lifestyle factors, and long-term disease management needs to improve adherence and outcomes.
A panelist presents a case of severe seborrheic dermatitis in a young man with facial and scalp involvement, demonstrating how a once-daily, foam-based phosphodiesterase-4 (PDE4) inhibitor provided rapid, complete clearance and itch relief, highlighting the importance of efficacy, cosmetic acceptability, and quality-of-life considerations in treatment selection.
A panelist presents a case of severe, chronic facial seborrheic dermatitis in a young man, highlighting diagnostic challenges and emotional impact, and illustrating how daily use of a phosphodiesterase-4 (PDE4) inhibitor foam led to near-clearance and symptom relief by 8 weeks, underscoring the therapy’s effectiveness, safety, and adaptability to patient preferences.
A panelist discusses a case of moderate seborrheic dermatitis in a 34-year-old African American woman, emphasizing the need for individualized, culturally sensitive treatment plans that accommodate hair type and styling preferences, illustrating how an intermittent ketoconazole shampoo regimen aligned with her routine led to symptom improvement.
A panelist highlights emerging therapies such as phosphodiesterase-4 (PDE4) and topical Janus kinase (JAK) inhibitors that target shared inflammatory pathways across skin diseases, emphasizing their potential to simplify and improve seborrheic dermatitis management with safer, more convenient options and a promising pipeline of treatments on the horizon.
